Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials

BACKGROUND: Adding docetaxel to androgen deprivation therapy (ADT) improves survival in patients with metastatic, hormone-sensitive prostate cancer, but uncertainty remains about who benefits most. We therefore aimed to obtain up-to-date estimates of the overall effects of docetaxel and to assess wh...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Vale, Claire L, Fisher, David J, Godolphin, Peter J, Rydzewska, Larysa H, Boher, Jean-Marie, Burdett, Sarah, Chen, Yu-Hui, Clarke, Noel W, Fizazi, Karim, Gravis, Gwenaelle, James, Nicholas D, Liu, Glenn, Matheson, David, Murphy, Laura, Oldroyd, Robert E, Parmar, Mahesh K B, Rogozinska, Ewelina, Sfumato, Patrick, Sweeney, Christopher J, Sydes, Matthew R, Tombal, Bertrand, White, Ian R, Tierney, Jayne F
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2023
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7616350/
https://ncbi.nlm.nih.gov/pubmed/37414011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(23)00230-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller